• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by PROCEPT BioRobotics Corporation

    11/14/25 11:37:05 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care
    Get the next $PRCT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    PROCEPT BioRobotics Corp

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    74276L105

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    74276L105


    1Names of Reporting Persons

    AllianceBernstein L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,204,599.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,391,688.00
    8Shared Dispositive Power

    28,096.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,419,784.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox checked
    11Percent of class represented by amount in row (9)

    6.1 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PROCEPT BioRobotics Corp
    (b)Address of issuer's principal executive offices:

    150 BAYTECH DRIVE,, SAN JOSE,, CA, 95134
    Item 2. 
    (a)Name of person filing:

    AllianceBernstein L.P. ("AllianceBernstein L.P.")
    (b)Address or principal business office or, if none, residence:

    501 Commerce Street, Nashville, TN 37203 All media outlets, please contact Jennifer Will at AllianceBernstein (212-969-1157) with any questions. All other questions can be directed to [email protected].
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    74276L105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    3,419,784 shares acquired solely for investment purposes on behalf of client discretionary investment advisory accounts.* *AllianceBernstein L.P. is a majority owned subsidiary of Equitable Holdings, Inc. ("EQH"). AllianceBernstein operates under independent management and makes independent decisions from EQH and its respective subsidiaries, and EQH calculates and reports beneficial ownership separately from AllianceBernstein pursuant to guidance provided by the Securities and Exchange Commission in Release Number 34-39538 (January 12, 1998).
    (b)Percent of class:

    6.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    3,204,599

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    3,391,688

     (iv) Shared power to dispose or to direct the disposition of:

    28,096

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    AllianceBernstein L.P.
     
    Signature:Melissa Guerra
    Name/Title:VP/Director of Compliance
    Date:11/13/2025
    Get the next $PRCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRCT

    DatePrice TargetRatingAnalyst
    3/6/2026$30.00Neutral
    Robert W. Baird
    2/26/2026Outperform → Perform
    Oppenheimer
    2/26/2026$20.00Neutral → Underperform
    BofA Securities
    12/12/2025$62.00Buy
    UBS
    12/8/2025$38.00Buy → Neutral
    BofA Securities
    9/2/2025$60.00Perform → Outperform
    Oppenheimer
    7/9/2025$70.00Overweight
    Stephens
    7/7/2025Perform
    Oppenheimer
    More analyst ratings

    $PRCT
    SEC Filings

    View All

    SEC Form 144 filed by PROCEPT BioRobotics Corporation

    144 - PROCEPT BioRobotics Corp (0001588978) (Subject)

    3/17/26 3:14:14 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PROCEPT BioRobotics Corporation

    SCHEDULE 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    3/6/26 10:05:20 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by PROCEPT BioRobotics Corporation

    S-8 - PROCEPT BioRobotics Corp (0001588978) (Filer)

    2/26/26 4:51:15 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Nouri Alaleh

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/19/26 5:47:08 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Nouri Alaleh

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/19/26 4:25:58 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Waters Kevin

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/19/26 4:25:16 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Robert W. Baird initiated coverage on PROCEPT BioRobotics with a new price target

    Robert W. Baird initiated coverage of PROCEPT BioRobotics with a rating of Neutral and set a new price target of $30.00

    3/6/26 8:35:41 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics downgraded by Oppenheimer

    Oppenheimer downgraded PROCEPT BioRobotics from Outperform to Perform

    2/26/26 7:23:22 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics downgraded by BofA Securities with a new price target

    BofA Securities downgraded PROCEPT BioRobotics from Neutral to Underperform and set a new price target of $20.00

    2/26/26 7:11:50 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy

    SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT), today announced the international expansion of the HYDROS Robotic System, the company's next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH). HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the system enables surgeons to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility. The platform is designed to support scalable adoption across care setti

    3/12/26 9:00:00 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth

    Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased organizational disciplineStrong revenue outlook, procedure growth, expanding margins, and path to profitabilityLonger-term growth drivers include market expansion and expanded application into prostate cancer NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today hosted its 2026 Investor Day event in New York to detail the Company's market opportunity, long-term strategy and growth goa

    2/26/26 7:55:00 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance

    SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. "In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter," said Larry Wood, Chief Executive Officer. "At the same time, we took meaningful steps to position the Company for its next phase of growth. To sharpen our focus on delivering durable procedure growth, we realigned our commer

    2/25/26 4:02:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Desai Antal Rohit bought $10,482,943 worth of shares (426,262 units at $24.59) (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/9/26 7:19:42 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/14/24 1:28:32 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/12/24 5:01:10 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/4/24 1:31:19 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    Leadership Updates

    Live Leadership Updates

    View All

    Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

    SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

    10/28/24 7:00:00 AM ET
    $ISRG
    $PRCT
    $SNBR
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
    Home Furnishings

    Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism

    Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the

    8/15/24 10:00:00 AM ET
    $ISRG
    $PRCT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    Sonder Capital Appoints Kate Garrett as Managing Partner to Lead Next Generation of Growth

    Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit

    4/2/24 8:00:00 AM ET
    $ISRG
    $PRCT
    $SWAV
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    $PRCT
    Financials

    Live finance-specific insights

    View All

    PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance

    SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. "In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter," said Larry Wood, Chief Executive Officer. "At the same time, we took meaningful steps to position the Company for its next phase of growth. To sharpen our focus on delivering durable procedure growth, we realigned our commer

    2/25/26 4:02:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® Announces Updated Dates for 4Q25 Earnings Conference Call and Investor Day

    SAN JOSE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that it has updated the timing of its previously announced fourth quarter 2025 earnings conference call and Investor Day due to significant travel disruptions caused by inclement weather. The Company will report financial results for the fourth quarter of 2025 after market close on Wednesday, February 25, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it has r

    2/23/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City

    SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, February 24, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it will host an in-person investor day event on Wednesday, February 25, 2026, at the NASDAQ Headquarters in New York City beginning at 8:00am Eastern Time. Guests are encouraged to register in advance by clic

    1/26/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care